Reem Hospital successfully completes its inaugural Alzheimer's Disease clinical trial

Reem Hospital has announced the successful completion and database lock of its clinical trial, the TauRx TRx-237-805 study, a major investigation into the novel therapy Hydromethylthionine Mesylate (HMTM) for the management of Alzheimer’s disease, the most common form of dementia worldwide.

The trial was conducted in collaboration with Insights Research Organization & Solutions (IROS), a leading UAE-based contract research organization (CRO) and part of the M42 group, which oversaw the study’s end-to-end management. Advanced diagnostic tools were also utilised during the trial to identify early biomarkers of cognitive decline in individuals with a high genetic risk of developing Alzheimer’s disease.

Recommended For You

Abu Dhabi sees zero fog-related deaths since road alert system launched

Sharjah launches Dh2 million Faya Research Grant; eligibility, funding explained

Australian Open: Sinner on song, Keys through as Osaka makes bold statement

Creative Fusion showcases 100+ architectural models with 20+ developers at Cityscape 2025

UK: Katy Perry's ex-husband in court on two new rape charges

 

The completion of the study marks a significant institutional milestone for Reem Hospital, underscoring its growing capacity to contribute to global medical research and innovation. The trial’s primary objective was to assess the safety and tolerability of HMTM, with particular focus on its use within the local Emirati population.

Dr Amir Abdelghaffar, consultant neurologist, head of department, and principal investigator of the study at Reem Hospital, highlighted the importance of the achievement. "Successfully locking the database for the TRx-237-805 study is a direct testament to the perseverance and scientific excellence of the entire research team," he said. "The oral drug HMTM has been investigated for safety and tolerability through a rigorous and demanding research journey. While the clinical findings will speak for themselves, this milestone confirms our ability to conduct high-quality, audit-validated research, bringing hope and advanced therapeutic options closer to our patients and the wider community."

The trial’s success was further reinforced by a recent external audit conducted by the sponsor, which Reem Hospital passed successfully, reflecting the research team’s adherence to the highest standards of Good Clinical Practice (GCP).

Islam ElTantawy, general manager of IROS, said the collaboration reflects the UAE’s strengthening position in clinical research. "This partnership reinforces the UAE’s role as a leading hub for pioneering clinical research and innovation,” he said. “Conducting these trials in Abu Dhabi, alongside institutions such as Reem Hospital, demonstrates our shared commitment to advancing scientific discovery and addressing some of the most pressing health challenges of our time."

Chairman Zaid Al Siksek described the study as a defining moment for the hospital and the wider healthcare ecosystem. "The successful completion of our first-ever clinical trial is a transformative milestone for Reem Hospital and for healthcare in the region," he said. "Focused on the critical area of Alzheimer’s research, this achievement firmly establishes Reem Hospital as a dedicated hub for global medical innovation. It reflects our commitment to enhancing patient care not only through treatment, but through meaningful contributions to international scientific discovery."

The completion of the TRx-237-805 study is the result of sustained collaboration and collective effort across the entire research team, further positioning Abu Dhabi as an emerging centre for advanced clinical research.